Consensus recommendations for botulinum toxin injections in the spasticity management of children with cerebral palsy during COVID-19 outbreak

Abstract: Spasticity is the most common motor disturbance in cerebral palsy (CP). Lockdown in the COVID-19 outbreak has profoundly changed daily routines, and similarly caused the suspension of spasticity treatment plans. Besides, the delay in botulinum toxin (BoNT) injection, which is important in the management of focal spasticity, led to some problems in children. This consensus report includes BoNT injection recommendations in the management of spasticity during the COVID-19 pandemic in children with CP. In order to develop the consensus report, physical medicine and rehabilitation (PMR) specialists experienced in the field of pediatric rehabilitation and BoNT injections were invited by Pediatric Rehabilitation Association. Items were prepared and adapted to the Delphi technique by PMR specialists. Then they were asked to the physicians experienced in BoNT injections (PMR specialist, pediatric orthopedists, and pediatric neurologists) or COVID-19 (pediatric infectious disease, adult infectious disease). In conclusion, the experts agree that conservative management approaches for spasticity may be the initial steps before BoNT injections. BoNT injections can be administered to children with CP with appropriate indications and with necessary precautions during the pandemic.Key words: Botulinum toxin, cerebral palsy, COVID-19, pandemic, spasticity

PDF

___

1. Dy R, Roge D. Medical updates in management of hypertonia. Physical Medicine and Rehabilitation Clinics of North America 2020; 31 (1): 57-68. doi: 10.1016/j.pmr.2019.09.010
2. Reebye R, Finlayson H, May C, Satkunam L, Wein T et al. Practical guidance for outpatient spasticity management during the coronavirus (COVID-19) pandemic: canadian spasticity COVID-19 task force. Canadian Journal of Neurological Sciences 2020; 1-17. doi: 10.1017/cjn.2020.104
3. Baricich A, Santamato A, Picelli A, Morone G, Smania N et al. Spasticity treatments during COVID-19 pandemic: clinical recommendations. Frontiers in Neurology 2020; 11: 719. doi: 10.3389/fneur.2020.00719
4. Blumetti FC, Belloti JC, Tamaoki MJ, Pinto JA. Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy. Cochrane Database Systematic Reviews. 2019; 10(10): CD001408. doi: 10.1002/14651858.CD001408
5. Helmich RC, Bloem BR. The impact of the COVID-19 pandemic on Parkinson’s disease: hidden sorrows and emerging opportunities. Journal of Parkinsons Disease 2020; 10 (2): 351-354. doi: 10.3233/JPD-202038
6. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatric Pulmonology 2020; 55 (5): 1169-1174. doi: 10.1002/ppul.24718
7. Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World Journal of Pediatrics 2020; 16 (3): 240-246. doi: 10.1007/s12519-020- 00345-5
8. Shen KL, Yang YH, Jiang RM, Wnag TY, Zhao DC et al. Updated diagnosis, treatment and prevention of covid-19 in children: experts’ consensus statement (condensed version of the second edition). World Journal of Pediatrics 2020; 16 (3): 232-239. doi: 10.1007/s12519-020-00362-4
9. Souza TH, Nadal JA, Nogueira RJN, Pereira RM, Brandao MB.Clinical manifestations of children with COVID-19: a systematic review. PediatricPulmonology 2020; 55 (8): 1892- 1899. doi10.1002/ppul.24885
10. She J, Liu L, Liu W. COVID-19 epidemic: disease characteristics in children. Journal of Medical Virology 2020; 92: 747-754.doi: 10.1002/jmv.25807
11. Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. Journal of American Medical Association Pediatrics 2020; 174 (9): 868- 873. doi: 10.1001/jamapediatrics.2020.1948
12. Oualha M, Bendavid M, Berteloot L, Corsia A, Lesage F et al. Severe and fatal forms of COVID-19 in children. Archives of Pediatrics 2020; 27: 235-238. doi: 10.1016/j.arcped.2020.05.010
13. Parri N, Magista AM, Marchetti F, Cantoni B, Arrighini A et al. Characteristic of COVID-19 infection in pediatric patients: early findings from two italian pediatric research networks. European Journal of Pediatrics 2020; 1315-1329. doi: 10.1007/ s00431-020-03683-8
14. Carda S, Invernizzi M, Bavikatte G, Deltombe T, Draulans N et al. COVID-19 pandemic. What should PRM specialists do? A clinician’s perspective. European Journal of Physical and Rehabilitation Medicine 2020; 56 (4): 515-524. doi: 10.23736/ S1973-9087.20.06317-0
15. Bertamino M, Cornaglia S, Zanetti A, Rocco AD, Ronchetti A et al. Impact on rehabilitation programs during COVID-19 containment for children with pediatric and perinatal stroke. European Journal of Physical and Rehabilitation Medicine 2020; 56 (5): 692-694. doi: 10.23736/S1973- 9087.20.06407-2
16. Novak I, Cusick A, Lannin N. Occupational therapy home programs for cerebral palsy: double-blind, randomized, controlled trial. Pediatrics 2009; 124: e606-14. doi: 10.1542/ peds.2009-0288
17. Veverka T, Hok P, Otruba P, Zapletalová J, Kukolova B, Tüdes Z et al. Botulinum toxin modulates posterior parietel cortex activation in post stroke spasticity of upper limb. Frontiers in Neurology 2019; 10: 495. doi: 10.3389/fneur.2019.00495
18. Multani I, Manji J, Hastings-IsonT, Khot A, Graham K. Botulinum toxin in the management of children with cerebral palsy. Pediatric Drugs 2019; 21 (4): 261-281. doi: 10.1007/ s4027-019-00344-8
19. Lima CMAO. Information about the new coronavirus disease (COVID-19). Radiolagia Brasileira 2020; 53 (2): V-VI. doi: 10.1590/0100-3984.2020.53.2e1
20. Montastruc J, Marque P, Moulis F, Bourg V, Lambert V et al. Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy: a pharmaco-epidemiological study in VigiBase. Developmental Medicine and Child Neurology 2017; 59 (3): 329-334. doi: 10.111/dmcn.13286
21. Blaszczyk I, Foumani NP, Ljungberg C, Wiberg M. Questionnaire about the adverse events and side effects following botulinum toxin A treatment in patients with cerebral palsy. Toxins (Basel) 2015; 7 (11): 4645-4654. doi: 10.33.90/toxins7114645
22. Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I et al. The updated european consensus 2009 on the use of botulinum toxin for children with cerebral palsy. European Journal of Paediatric Neurology 2010; 14: 45-66. doi: 10.1016/j. ejpn.2009.09.005
23. Nair R, Aggarwal R, Khanna D. Methods of formal consensus in classification/diagnostic criteria and guideline development. Seminars in Arthritis and Rheumatism 2011; 41 (2): 95-105. doi: 10.1016/j.semarthrit.2010.12.001
24. Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J et al. Standardized reporting of clinical practice guidelines: a proposal from the conference on guideline standardization. Annals of Internal Medicine 2003; 139 (6): 493-4988. doi: 10.7326/0003-4819-139-6-200309160-00013
25. Jünger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on conducting and reporting delphi studies (CREDES) in palliative care: Recommendations based on a methodological systematic review. Palliative Medicine 2017; 31 (8): 684-706. doi: 10.1177/0269216317690685
26. Eriksen MB, Frandsen TF. The impact of patient, intervention, comparison,outcome as search strategy tool on literature search quality on literature search quality: a systematic review. Journal of the Medical Library Association 2018; 106 (4). doi: 10.5195/jmla.2018.345
27. Tang LY, Wang J. Anesthesia and COVID-19: What we should know and what we should do. Seminars in Cardiothoracic and Vascular Anesthesia 2020; 24 (2): 127-137. doi: 10.1177/1089253220921590
28. Naidu K, Smith K, Sheedy M, Adair B, Yu X, Graham HK. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy. Developmental Medicine and Child Neurology 2010; 52 (2): 139-144. doi: 10.111/j.1469- 8749.2009.03583.x
29. Paget SP, Swinney CM, Burton KLO, Bau K, O’Flaherty SJ. Systemic adverse events after botulinum neurotoxin A injections in children with cerebral palsy. Developmental Medicine and Child Neurology 2018; 60 (11): 1172-1177. doi: 10.1111/dmcn.13995
30. Papavasiliou AS, Nikaina I, Foska K, Bouros P, Mitsou G et al. Safety of botulinum toxin A in children and adolescents with cerebral palsy in a pragmatic setting. Toxins 2013; 5: 524-536. doi: 10.3390/toxins5030524
31. Pandey, AS,Ringer AJ, Rai AT, Kan P, Jabbour P et al. Minimizing sars-cov-2 exposure when performing surgical interventions during the COVID-19 pandemic. Journal of Neurointerventional Surgery 2020; 12 (7): 643-647. doi: 10.1136/neurointsurg.2020-016161
32. Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. Journal of American Medical Association 2020; 323 (16): 1610- 1612. doi: 10.1001/jama.2020.3227
33. Reebye R, Finlayson H, May C, Satkunam L, Wein T et al. Practical guidance for outpatient spasticity management during the coronavirus (COVID-19) pandemic: canadian spasticity COVID-19 task force. Canadian Journal of Neurological Sciences 2020; 1-5. doi: 10.1017/cjn.2020.104
34. Fraise AP, Lambert PA, Maillard JY. Russell, Hugo and Ayliffe’s Principles and Practice of Disinfection, Preservation and Sterilization. 4th ed. Blackwell. doi: 10.1002/9780470755884
35. Allam AE, Ergonenc T, Martos AG, Perez MF, Perdisa F, Porta F et al. Ultrasound-guided interventions during the COVID-19 pandemic - a new challenge. American Journal of Physical Medicine and Rehabilitation 2020; 99 (7): 580-581 .doi: 10.1097/PHM.0000000000001467
36. Bajwa SJS, Sarna R, Bawa C, Mehdiratta L. Peri-operative and critical care concerns in coronavirus pandemic. Indian Journal of Anaesthesia 2020; 64 (4): 267-274. doi: 10.4103/ija.IJA-272- 20
37. Kilicaslan A, Kekec AF, Eren AS, Uzun ST. Peripheral nerve blocks in a patient with suspected COVID-19 infection. Journal of ClinicalAnesthesia2020; 65: 109853. doi: 10.1016/j. jclinane2020.109853
38. Kandasamy M. Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate covid-19. Medicine in Drug Discovery 2020; 6: 100042. doi: 10.1016/j.medidd.2020.100042
39. John Abrams. Coronavirus (the invisible killer). Libera Publishing (2020) ebook ISBN: 9783969175767
40. Wang W, Xu Y, Gao R, Ru L, Han K et al. Detection of SARSCoV-2 in different types of clinical specimens. Journal of American Medical Association 2020; 323 (18): 1843-1844. doi: 10.1001/ jama.2020.3786
41. Lu X, Zhang L, Du H, Zhang J, Li Y et al. Sars-cov-2 infection in children. New England Journal of Medicine 2020; 382: 1663. doi: 10.1056/NEJMc2005073
42. Çiftçi E, Arga G. Çocuklarda COVID-19. In: Memikoğlu O, Genç V (editors) COVID 19. Ankara Üniversitesi Tıp Fakültesi Yayını (2020); 127-135 (in Turkish). ISBN : 978-605-136-477-3